Table 1 Patient baseline characteristics
N (%) | Total | Never smoker | 0< PYa ≤10 | 10<PYa ≤30 | > 30a PY | p-value |
|---|---|---|---|---|---|---|
142 | 91(64.1) | 12(8.5) | 22(15.5) | 17(11.9) | ||
Age | 65(54.5–75.7) |  |  |  |  |  |
  < 60 years | 49(34.5) | 33(36.3) | 3(25) | 8(36.4) | 5(29.4) | 0.842 |
  ≥ 60 years | 94(65.5) | 58(63.7) | 9(75) | 14(63.6) | 12(70.6) | |
Sex | ||||||
 male | 50(35.2) | 10(11) | 8(66.7) | 18(81.8) | 14(82.4) | 0.001 |
 Female | 92(64.8) | 81(89) | 4(33.3) | 4(18.2) | 3(17.6) | |
ECOG | ||||||
 0–1 | 123(86.6) | 81(89) | 11(91.7) | 19(86.4) | 12(70.6) | 0.23 |
  ≥ 2 | 19(13.4) | 10(11) | 1(8.3) | 3(13.6) | 5(29.4) | |
Stageb | ||||||
 recurrent | 15(10.5) | 12(13.2) | 19(8.3) | 1(4.5) | 1(5.9) | 0.33 |
 IIIA | 7(4.9) | 5(5.5) | 1(8.3) | 1(4.5) | 0(0) | |
 IIIB | 12(8.5) | 8 (8.8) | 0(0) | 0(0) | 4(23.5) | |
 IV | 108(76.1) | 66(72.5) | 10(83.3) | 20(90.9) | 12(70.6) | |
  M1a | 40(37) | 24(36.4) | 3(30) | 7(35) | 6(50.0) | 0.77 |
  M1b | 68(63) | 42(63.6) | 7(70) | 13(65) | 6(50.0) | |
Time of EGFR-TKI treatment | ||||||
 First line | 84(59.2) | 60(65.9) | 6(50) | 11(50) | 7(41.2) | 0.16 |
 Second or higher line | 58(40.8) | 31(34.1) | 6(50) | 11(50) | 10(58.8) | |
EGFR mutation | ||||||
 19 del | 91(64.1) | 59(64.8) | 10(83.3) | 13(59.1) | 9(52.9) | 0.38 |
 21 L858R | 51(35.9) | 32(35.2) | 2(16.7) | 9(40.9) | 8(47.1) | |
Type of EGFR TKI | ||||||
 Gefitinib | 107(75.4) | 71(78) | 6(50.0) | 17(77.3) | 13(76.5) | 0.53 |
 Erlotinib | 17(12) | 9(9.9) | 2(16.7) | 3(13.6) | 3(17.6) | |
 Afatinib | 14(9.9) | 9(9.9) | 3(21.4) | 1(4.5) | 1(5.9) | |
 Osimertinib | 4(2.7) | 2(2.2) | 1(8.3) | 1(4.5) | 0(0.0) | |
Brain metastasis | ||||||
 Yes | 42(29.6) | 26(28.6) | 5(41.1) | 9(40.9) | 2(11.8) | 0.19 |